BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Neocentromeres, Doxycycline, rs2300478, NEUROG3, cell-cell adhesion, Ischemia, Neuron)
Bookmark Forward

QuickView for CXCL9 (gene)


Body Atlas

Most Correlated Tissues

  1. Superior cervical ganglion
  2. Skeletal muscle psoas
  3. Appendix
  4. Atrioventricular node
  5. Ciliary ganglion
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Protozoan infection
  2. Severe acute respiratory syndrome
  3. Viral disease
  4. Kidney transplant failure and rejection
  5. Herpes simplex type 2 infection
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. IgG2A
  2. Interferon-gamma
  3. enterotoxin B, staphylococcal
  4. lipopolysaccharide, E coli O55-B5
  5. enterotoxin I, staphylococcal
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. Pdgfrb
  2. TAGAP
  3. BATF3
  4. USP6
  5. ZNF112
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Split-Combine Click-SELEX Reveals Ligands Recognizing the Transplant Rejection Biomarker CXCL9.
  2. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
  3. Highly Sensitive Immuno-CRISPR Assay for CXCL9 Detection.
  4. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte t…
  5. Gut Epithelial-derived CXCL9 Maintains Gut Homeostasis Through Preventing Overgrown E. coli.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Use of CXCL9 as a Biomarker of Acthar Efficacy
  2. Tregs CD25 CXCL9 in Vitiligo
  3. CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions
  4. CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome
  5. CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Explore Clinical Trials Results
  • Copyright © 2023 Illumina Inc. All rights reserved.